IYH Beats IXJ on Returns While Global Fund Offers Higher Yield

As of September 28, 2026, the iShares U.S. Healthcare ETF (IYH) returned 28.8% over the trailing year versus 22.5% for the global IXJ, and $1,000 invested over five years grew to $1,394 versus $1,329. IXJ had a higher trailing yield of 1.4% versus 1.1%, while expense ratios were nearly identical at 0.38% and 0.37%, respectively; five-year maximum drawdowns and betas were also similar. The comparison highlights a trade-off between IYH’s stronger reported returns and IXJ’s international diversification and higher income, with foreign-currency exposure a risk for IXJ.

Analysis

The decision is less “U.S. versus global healthcare” than whether to accept extra exposure to a few U.S. mega-cap drugmakers. The supplied weights put LLY at 14.6% in IYH versus 10.5% in IXJ, so a change in GLP-1 expectations or LLY’s valuation can drive a meaningful relative-return gap even if the wider healthcare sector is stable. IXJ’s shared large holdings mean it is not a clean hedge against U.S. pharma-specific risk; its benefit depends on the non-U.S. holdings and currency exposure, which the article does not quantify. Verify country weights, FX hedging, and index methodology before treating it as genuine geographic diversification.

The apparent U.S. outperformance is not, by itself, evidence of a durable sector advantage: concentration and a handful of highly valued growth names can explain much of the difference. Conversely, a higher IXJ distribution yield is only a modest cushion, not a material income thesis. The source also calls these ETFs healthcare REIT options and later describes yields as similar despite its own table showing a gap; treat its characterization as unreliable and confirm fund data directly.

Near term, relative performance will likely remain sensitive to mega-cap drug sentiment. Over 1–3 months, watch LLY estimate revisions and fund flows; over 6–18 months, patent exposure and the geographic mix matter more. A thesis favoring IXJ is falsified if verified non-U.S. exposure is small or FX losses erase the diversification benefit. No strong directional trade follows from the evidence provided.

Key Decisions for Investors

• No standalone long/short trade on these figures: the funds share major holdings, and the incremental yield difference is not enough to establish an attractive risk/reward.
• For a new healthcare allocation, use IXJ only if verified country and currency exposures deliver the intended diversification; otherwise, IYH’s higher LLY weight is an active concentration choice, not simply a domestic-sector proxy.
• Monitor LLY estimate revisions and relative performance: sustained upward revisions would support IYH’s greater exposure, while a sharp GLP-1 expectation reset would make IXJ relatively less exposed, all else equal.
• Before acting, reconcile the article’s yield and fund-category inconsistencies against issuer holdings and distribution data; reassess if actual non-U.S. weights or FX treatment differ materially from the diversification thesis.